Clorox (NYSE:CLX) Price Target Raised to $161.00

Clorox (NYSE:CLX) had its target price boosted by investment analysts at Wells Fargo & Company from $157.00 to $161.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 0.75% from the stock’s previous close.

CLX has been the topic of a number of other reports. TD Cowen upgraded Clorox from a “sell” rating to a “hold” rating and raised their price objective for the stock from $155.00 to $170.00 in a report on Wednesday, November 6th. StockNews.com lowered shares of Clorox from a “buy” rating to a “hold” rating in a report on Sunday, January 5th. DA Davidson raised their target price on Clorox from $153.00 to $171.00 and gave the company a “neutral” rating in a report on Monday, November 4th. Royal Bank of Canada reissued a “sector perform” rating and set a $150.00 price target on shares of Clorox in a research report on Thursday, January 30th. Finally, Barclays reduced their target price on shares of Clorox from $139.00 to $130.00 and set an “underweight” rating on the stock in a research report on Friday, January 17th. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Clorox currently has an average rating of “Hold” and a consensus target price of $156.36.

Clorox Trading Up 0.7 %

NYSE CLX opened at $159.80 on Tuesday. Clorox has a 12 month low of $127.60 and a 12 month high of $171.37. The company has a 50-day moving average of $162.76 and a 200-day moving average of $158.50. The company has a market cap of $19.78 billion, a P/E ratio of 55.68, a P/E/G ratio of 2.92 and a beta of 0.42. The company has a debt-to-equity ratio of 11.08, a current ratio of 1.00 and a quick ratio of 0.62.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Monday, February 3rd. The company reported $1.55 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.16. Clorox had a net margin of 4.78% and a return on equity of 316.08%. During the same quarter in the prior year, the company earned $2.16 EPS. As a group, equities analysts predict that Clorox will post 6.86 earnings per share for the current year.

Institutional Trading of Clorox

Several institutional investors have recently added to or reduced their stakes in CLX. Brooklyn Investment Group grew its position in shares of Clorox by 163.8% during the 4th quarter. Brooklyn Investment Group now owns 153 shares of the company’s stock valued at $25,000 after buying an additional 95 shares during the last quarter. Prospera Private Wealth LLC acquired a new position in Clorox in the third quarter valued at approximately $27,000. Continuum Advisory LLC grew its holdings in shares of Clorox by 300.0% during the third quarter. Continuum Advisory LLC now owns 184 shares of the company’s stock valued at $30,000 after purchasing an additional 138 shares during the last quarter. Asset Planning Inc acquired a new stake in shares of Clorox during the 4th quarter worth approximately $32,000. Finally, Carolina Wealth Advisors LLC bought a new stake in shares of Clorox in the 3rd quarter worth approximately $48,000. Institutional investors own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.